nyuuzyou/wikis huggingface dataset:
University of Cincinnati Medical Center Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
==Basic information==
Name: University of Cincinnati Hematology Oncology Fellowship Program
Fellowship program website: https://www.med.uc.edu/intmed/divisions/hematology-oncology/fellowship
ACGME ID: ___
===Leadership===
*Program Director: ___
*Associate Program Director: ___
===Fellowship Coordinator===
___
Telephone: ___
Email: ___
==Application process and requirements==
===Process===
*Applications accepted starting on: ___
*Application deadline: ___
*Applications submitted through ERAS
===Requirements===
==Statistics==
*Number of fellowship positions available per year: ___
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
==Testimonials==
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
University of Colorado Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
==Basic information==
Name: University of Colorado Hematology/Medical Oncology Fellowship Program 
Fellowship program website: https://www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/MedicalOncology/Education/Pages/default.aspx
ACGME ID: 1550721096
===Leadership===
*Program Director: Daniel Bowles, MD
===Fellowship Coordinator===
Brianne Johnson, MBA​​
Phone: 303-724-9238 ​​​​​​​​
Email: brianne.n2.johnson@ucdenver.edu
==Application process and requirements==
https://www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/MedicalOncology/Education/Pages/ApplicationProcess.aspx
===Process===
*Applications accepted starting in: July
*Application deadline:
*Applications submitted through ERAS
===Requirements===
Required Documents for All Applicants:
*Four Letters of Recommendation (including program director letter)
*Curriculum Vitae
*Medical Student Performance Evaluation (MSPE)
*USMLE Transcript or COMLEX Transcript
*Personal Statement
*Transcripts of Medical Education
Additional Documents for Foreign Medical School Applicants: 
*Foreign Medical License
*ECFMG Status Report
==Statistics==
*Number of fellowship positions available per year: 4
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
https://www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/MedicalOncology/Education/Pages/Curriculum.aspx
===Year 1===
Trainees divide their time in 3 month blocks at University of Colorado Hospital, Denver Health, and the VA
Two blocks at UCH are divided into solid tumor oncology and benign and malignant hematology
Third block is electives
===Year 2===
Year two comprises of training according to different tracks 
*Clinical Investigator Research
*Clinical Excellence and Quality Improvement
*Laboratory Based Research
*BMT
===Year 3===
Devoted to completion of the research training for those in the research tracks and to broadening the clinical experience of those in the clinical track.
==Affiliated medical facilities==
University of Colorado Hospital
Denver Health
VA hospital
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
University of Massachusetts Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The Division of Hematology and Medical Oncology offers several fellowship training opportunities. Each program focuses on teaching the most cutting-edge practices related to research and clinical medicine, while encouraging fellows to take advantage of the collaborative environment at UCSF and the Helen Diller Comprehensive Cancer Center to prepare them for successful academic careers. We believe training future leaders in hematology and oncology is our responsibility and contributes to the vitality and advancement of the field."
==Basic information==
Name: University of Massachusetts Hematology Oncology Fellowship
Fellowship program website: https://www.umassmed.edu/hema_oncology/fellowship/
ACGME ID: 1552421075
===Leadership===
*Program Director: Venu Bathini, MD
*Associate Program Director: Bradley Switzer, MD
===Fellowship Coordinator===
UMass Medical School
55 Lake Ave North
Worcester, MA 01655
Phone: (774) 443-7433 
Fax: (774) 443-2298
==Application process and requirements==
===Process===
*Applications accepted starting on:
*Application deadline:
*Applications submitted through ERAS
===Requirements===
The following should be included:
* Common Application Form
* Curriculum Vitae
* Personal statement
* Three letters of recommendations preferably by Hematology-Oncology professors
* Deans Letter
* Transcripts
* USMLE or COMLEX Scores
For International Medical Graduates:
* Valid ECFMG certificate
* Scores of Parts I, II and III & USMLE or COMLEX
* Clinical experience in internal medicine in the United States (or Canada if Canadian citizen)
* Fluency in spoken and written English since communication skills are the core of internal medicine and Hematology-Oncology
* Good USMLE scores
* Letters of recommendations from U.S. physicians familiar with applicant's work preferably in Hematology-Oncology
* Accepts J1 visa, will very rarely sponsor H1-B visa
==Statistics==
*Number of fellowship positions available per year:
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*UMass Memorial Medical Center
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Upper tract urothelial carcinoma - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main UTUC page for regimens that include active anticancer treatment.
=Adjuvant therapy=
==Observation==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Ito et al. 2013 (THP Monotherapy Study Group Trial)	2005-2008 	Randomized Phase 2 (C)	Intravesicular pirarubicin	Seems to have shorter RFS
Birtle et al. 2020 (POUT) 	2012-2017 	Phase 3 (C) 	1a. GC1b. GCb 	Shorter DFS
No further antineoplastic treatment.
====Preceding treatment====
*Nephroureterectomy
===References===
#THP Monotherapy Study Group Trial: Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, Namiki S, Namima T, Ikeda Y, Kambe K, Kyan A, Ueno S, Orikasa K, Katoh S, Adachi H, Tokuyama S, Ishidoya S, Yamaguchi T, Arai Y. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol. 2013 Apr 10;31(11):1422-7. Epub 2013 Mar 4. link to original article EuroPMC UMIN000004039
#POUT: Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, Chakraborti P, Donovan JL, Elliott PA, French A, Jagdev S, Jenkins B, Keeley FX Jr, Kockelbergh R, Powles T, Wagstaff J, Wilson C, Todd R, Lewis R, Hall E. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020 Apr 18;395(10232):1268-1277. Epub 2020 Mar 5. link to original article link to PMC article EuroPMC NCT01993979
##Update: Birtle AJ, Jones R, Chester J, Lewis R, Biscombe K, Johnson M, Blacker A, Bryan RT, Catto JWF, Choudhury A, Das P, Jagdev S, Powles T, Wagstaff J, Cheung KC, Cafferty F, Hall E. Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. J Clin Oncol. 2024 May 1;42(13):1466-1471. Epub 2024 Feb 13. link to original article link to PMC article EuroPMC
Category:Upper tract urothelial carcinoma regimens
Category:Disease-specific pages
Category:Urothelial carcinomas
Category:Null regimens
Uracil mustard

==General information==
Class/mechanism: Alkylating agent
Route: PO
Extravasation: n/a
==Diseases for which it was used==
*Chronic lymphocytic leukemia
==History of changes in FDA indication==
*1962-09-13: Initial FDA approval
==Also known as==
*Generic name: uramustine
Category:Drugs
Category:Oral medications
Category:Alkylating agents
Category:Chronic lymphocytic leukemia medications (historic)
Category:FDA approved in 1962
Category:Discontinued drugs
Category:Stub
Uridine triacetate (Vistogard)

==General information==
Class/mechanism: Pyrimidine analog, antidote to Fluorouracil (5-FU) and Capecitabine (Xeloda). Uridine triacetate is an acetylated pro-drug of uridine. After oral administration, uridine triacetate is deacetylated into uridine, which competitively inhibits cell damage and cell death caused by fluorouracil/capecitabine.Uridine triacetate (Vistogard) package insertUridine triacetate (Vistogard) package insert (locally hosted backup)Vistogard manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Dosing==
*Adults: Uridine triacetate (Vistogard) 10 g PO every 6 hours x 20 doses
*Pediatric patients: Uridine triacetate (Vistogard) 6.2 g/m2 (maximum of 10 g per dose) PO every 6 hours x 20 doses
==Diseases for which it is used==
*Overdose of, or early-onset, severe, or life-threatening toxicity from fluorouracil or capecitabine.
==Patient drug information==
*Uridine triacetate (Vistogard) package insert
==History of changes in FDA indication==
*2015-12-11: Approved for patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms
*2015-12-11: Approved for patients who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or earlyonset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.
==Also known as==
*Brand name: Vistogard
==References==
Category:Drugs
Category:Oral medications
Category:Pyrimidine analogs
Category:Chemotherapy protective agents
Category:FDA approved in 2015
Vadastuximab talirine (SGN-CD33A)

==General information==
Class/mechanism from the NCI Drug Dictionary: An immunoconjugate consisting of a humanized monoclonal antibody that is engineered to contain cysteine residues that are conjugated to the synthetic, DNA cross-linking, pyrrolobenzodiazepine dimer SGD-1882, via the protease-cleavable linker maleimidocaproyl-valine-alanine dipeptide, with potential antineoplastic activity. The monoclonal antibody portion of the vadastuximab talirine specifically binds to the cell surface antigen CD33. This causes the internalization of vadastuximab talirine, and the release of the cytotoxic moiety SGD-1882. SGD-1882 binds to and crosslinks DNA, which results in both cell cycle arrest and the induction of apoptosis in CD33-expressing tumor cells. CD33, a transmembrane receptor, is expressed on myeloid leukemia cells.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Also known as==
*Code name: 33A, SGN-CD33A
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-CD33 antibody-drug conjugates
Category:Alkylating agents
Category:Acute myeloid leukemia medications (investigational)
Category:Halted drugs
Vadimezan (AS-A404)

==Mechanism of action==
From the NCI Drug Dictionary: A fused tricyclic analog of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. This agent also stimulates the anti-tumor activity of tumor-associated macrophages.
==Diseases for which is was unsuccessful==
*Non-small cell lung cancer
==Also known as==
*Code names: AS-1404, AS-A404
Category:Drugs
Category:Intravenous medications
Category:Vascular disrupting agents
Category:Investigational drugs
Category:Stub
Valacyclovir (Valtrex)

==General information==
Class/mechanism: Antiviral; prodrug of Acyclovir (Zovirax). Valacyclovir is absorbed by the gastrointestinal tract and undergoes first-pass intestinal and/or hepatic metabolism to become acyclovir and L-valine. Acyclovir is a synthetic purine nucleoside analog which interacts with the viral thymidine kinase (TK) encoded by herpes simplex virus types 1 and 2 (HSV-1 & HSV-2) and the varicella-zoster virus (VZV). Thymidine kinase converts acyclovir to acyclovir monophosphate, which is eventually converted via phosphorylation into acyclovir triphosphate. Acyclovir triphosphate inhibits the replication of viral DNA by prematurely terminating the replicating DNA strand since acyclovir has no 3' end; competitively inhibiting viral DNA polymerase; and inactivating viral DNA polymerase. Acyclovir has greater activity against HSV compared to VZV because of more robust phosphorylation by the HSV viral thymidine kinase.Valacyclovir (Valtrex) package insert Valacyclovir (Valtrex) package insert (locally hosted backup)
Route: PO
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
Frequently used for the prevention of reactivation of HSV or VZV during antineoplastic treatment. No known antineoplastic properties.
==Patient drug information==
*Valacyclovir (Valtrex) package insert PDF pages 23-28
*Valacyclovir (Valtrex) patient drug information (UpToDate)Valacyclovir (Valtrex) patient drug information (UpToDate)
==Also known as==
*Code name: BW-256U
*Generic names: acyclovir-valine, valaciclovir, valaciclovir Hcl, ValACV
*Brand names: Talavir, Valcivir, Valtrex, Virval, Zelitrex
==References==
Category:Drugs
Category:Oral medications
Category:Viral DNA synthesis inhibitors
Category:FDA approved in 1995
Valemetostat (Ezharmia)

==Mechanism of action==
From the NCI Drug Dictionary: The tosylate form of valemetostat, an orally available selective inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, valemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells.
==Diseases for which it is used==
*Adult T-cell leukemia-lymphoma
==History of changes in PMDA indication==
*2022-09-26: Newly indicated for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma. (Based on DS3201-A-J201)
==Also known as==
*Code name: DS-3201b
*Generic names: valemetostat tosilate, valemetostat tosylate
*Brand name: Ezharmia
Category:Drugs
Category:Oral medications
Category:EZH1 inhibitors
Category:EZH2 inhibitors
Category:Adult T-cell leukemia-lymphoma medications
Category:PMDA approved in 2022
Valganciclovir (Valcyte)

Antiviral with particular activity against cytomegalovirus (CMV).
==Also known as==
*Brand names: Cytomega, VagaCyte, Valcyclovir, Valcyte, Valgan, Valixa, Valnov, Virolfi, V-Gavir
Category:Drugs
Category:Oral medications
Category:Viral DNA synthesis inhibitors
Category:FDA approved in 2001
Valproate (Depakote)

==Diseases for which it was used==
*Acute myeloid leukemia
==Also known as==
*Generic name: valproic acid
*Brand names: Depacon, Depakine, Depakote, Encorate, Epibest, Epilim, Epival, Leeporate, Vallona, Valric
Category:Drugs
Category:Oral medications
Category:HDAC inhibitors
Category:Acute myeloid leukemia medications (historic)
Category:FDA approved in 1983
Category:Stub
Valrubicin (Valstar)

==General information==
Class/mechanism: Anthracycline; inhibits the incorporation of nucleosides, interferes with normal activity of DNA topoisomerase II, causing extensive chromosomal damage and cell cycle arrest in G2.Valrubicin (Valstar) package insertValrubicin (Valstar) package insert (locally hosted backup)Valstar manufacturer's site
Route: Intravesicular
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Patient drug information==
*Valrubicin (Valstar) manufacturer's patient drug information - "Understanding Your Therapy With VALSTAR"
*Valrubicin (Valstar) patient drug information (UpToDate)Valrubicin (Valstar) patient drug information (UpToDate)
==Diseases for which it is used==
*Bladder cancer
==History of changes in FDA indication==
* 1998-09-25: Initial FDA approval for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. (Based on Steinberg et al. 2000)
==Also known as==
*Code name: AD-32
*Brand names: Valstar, Valtaxin
==References==
Category:Drugs
Category:Intravesical medications
Category:Anthracyclines
Category:Bladder cancer medications
Category:FDA approved in 1998
Value frameworks

Note that the structure and content of HemOnc.org are constantly undergoing evolution, such that information that you read here might be outdated. This page was last reviewed and updated in December 2023.
=Introduction=
Several leading hematology/oncology societies and organizations have put forth value frameworks. Conceptually, these are approaches which are intended to combine measures of efficacy, toxicity, quality of life, and financial toxicity into a metric of value that can be used to influence treatment decisions. Our coverage of value frameworks will expand over time.
=ASCO Value Framework=
*2015: American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
*2016: Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received EuroPMC
=ESCAT=
*2018: A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
=ESMO Magnitude of Clinical Benefit Scale=
*2015 (Version 1.0): A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) EuroPMC
*2017 (Version 1.1): ESMO-Magnitude of Clinical Benefit Scale version 1.1
=NCCN Evidence Blocks=
*2016: NCCN Evidence Blocks EuroPMC
=Comparisons=
==ASCO Value Framework vs. ESMO-MCBS==
*2017: Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit? EuroPMC
==ASCO Value Framework vs. NCCN Evidence Blocks==
*2017: Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology EuroPMC
=Frequently asked questions=
Q: Do you plan to add value measures to HemOnc.org?
A: At some point in the future, we may add value measures to some regimens; however, given that these frameworks are recently introduced and undergoing frequent revision, we will continue to monitor their development, for now.
Category:Evidence-based oncology
Varlilumab (CDX-1127)

==General information==
Class/mechanism from NCI Drug Dictionary: A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of CDX-1127, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Also known as==
*Code name: CDX-1127
Category:Drugs
Category:Intravenous medications
Category:Anti-CD27 antibodies
Category:Investigational drugs